Nanoemulsion Speeds Herpes Labialis Healing

2009 ◽  
Vol 40 (5) ◽  
pp. 34
Author(s):  
MICHAEL KAUFMAN
Keyword(s):  
2017 ◽  
Vol 4 (1) ◽  
pp. 1-4
Author(s):  
Tejavathi Nagaraj ◽  
Lakshmi Balraj ◽  
Haritma Nigam ◽  
Sida Tagore
Keyword(s):  

Author(s):  
Alexander K.C. Leung ◽  
Benjamin Barankin
Keyword(s):  

2021 ◽  
pp. 1-13
Author(s):  
Eduardo Marques Zilli ◽  
Adrienne O’Donnell ◽  
Joel Salinas ◽  
Hugo J. Aparicio ◽  
Mitzi Michelle Gonzales ◽  
...  

Background: An association between chronic infectious diseases and development of dementia has been suspected for decades, based on the finding of pathogens in postmortem brain tissue and on serological evidence. However, questions remain regarding confounders, reverse causality, and how accurate, reproducible and generalizable those findings are. Objective: Investigate whether exposure to Herpes simplex (manifested as herpes labialis), Chlamydophila pneumoniae (C. pneumoniae), Helicobacter pylori (H. pylori), and cytomegalovirus (CMV) modifies the risk of dementia in a populational cohort. Methods: Questionnaires regarding incidence of herpes infections were administered to Original Framingham Study participants (n = 2,632). Serologies for C. pneumoniae, H. pylori, and CMV were obtained in Original (n = 2,351) and Offspring cohort (n = 3,687) participants. Participants are under continuous dementia surveillance. Brain MRI and neuropsychological batteries were administered to Offspring participants from 1999–2005. The association between each infection and incident dementia was tested with Cox models. Linear models were used to investigate associations between MRI or neuropsychological parameters and serologies. Results: There was no association between infection serologies and dementia incidence, total brain volume, and white matter hyperintensities. Herpes labialis was associated with reduced 10-year dementia risk (HR 0.66, CI 0.46–0.97), but not for the duration of follow-up. H. pylori antibodies were associated with worse global cognition (β –0.14, CI –0.22, –0.05). Conclusion: We found no association between measures of chronic infection and incident dementia, except for a reduction in 10-year dementia risk for patients with herpes labialis. This unexpected result requires confirmation and further characterization, concerning antiviral treatment effects and capture of episodes.


1973 ◽  
Vol 52 (1) ◽  
pp. 49-58 ◽  
Author(s):  
Aaron Honori Katcher ◽  
Vernon Brightman ◽  
Lester Luborsky ◽  
Irwin Ship

2014 ◽  
Vol 12 (3) ◽  
pp. 283-287 ◽  
Author(s):  
Christopher Downing ◽  
Jonathan Moayyad ◽  
Aparna Tamirisa ◽  
Stephen Tyring

2011 ◽  
Vol 24 (2) ◽  
pp. 103-109 ◽  
Author(s):  
JAMES P. MCCARTHY ◽  
WILLIAM D. BROWNING ◽  
CRAIG TEERLINK ◽  
GEORGE VEIT
Keyword(s):  

2003 ◽  
Vol 47 (3) ◽  
pp. 1072-1080 ◽  
Author(s):  
Spotswood L. Spruance ◽  
Terry M. Jones ◽  
Mark M. Blatter ◽  
Mauricio Vargas-Cortes ◽  
Judy Barber ◽  
...  

ABSTRACT Oral valacyclovir is better absorbed than oral acyclovir, increasing acyclovir bioavailability three- to fivefold. This provides the opportunity to explore whether high systemic acyclovir concentrations are effective in the treatment of cold sores (herpes labialis). Two randomized, double-blind, placebo-controlled studies were conducted. Subjects were provided with 2 g of valacyclovir twice daily for 1 day (1-day treatment), 2 g of valacyclovir twice daily for 1 day and then 1 g of valacyclovir twice daily for 1 day (2-day treatment), or a matching placebo and instructed to initiate treatment upon the first symptoms of a cold sore. In study 1, the median duration of the episode (primary endpoint) was reduced by 1.0 day (P = 0.001) with 1-day treatment and 0.5 days (P = 0.009) with 2-day treatment compared to placebo. Similarly, the mean duration of the episode was statistically significantly reduced by 1.1 days with 1-day treatment and 0.7 days with 2-day treatment compared to placebo. The proportion of subjects in whom cold sore lesion development was prevented and/or blocked was increased by 6.4% (P = 0.096) with 1-day treatment and 8.5% (P = 0.061) with 2-day treatment compared to placebo. The time to lesion healing and time to cessation of pain and/or discomfort were statistically significantly reduced with valacyclovir compared to placebo. In study 2, results similar to those in study 1 were obtained. AEs were similar across treatment groups. These studies provide evidence supporting a simple, 1-day valacyclovir treatment regimen for cold sores that is safe and effective. The 1-day valacyclovir regimen offers patients a unique and convenient dosing alternative compared to available topical therapies.


Sign in / Sign up

Export Citation Format

Share Document